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Background: Angiotensin receptor antagonists (ARB) improve outcomes in patients with systolic heart failure (HF), but may induce hyperkalemia 
(HK)and/or a worsening of renal function (WRF). We aimed at assessing the incidence and risk factors of HK and its inter-relationship with WRF, as 
well as associations with clinical outcome (death or admission for HF) in 3,846 HF patients enrolled in the double blind HEAAL trial (losartan 150 
mg/d vs. 50 mg/d).
Methods: Median follow-up was 4.7 years. Serum potassium and creatinine were assessed serially. Any episode of, any rise in serum K >5.5 or 5 
mmol/L defined HK and decrease in estimated glomerular filtration rate (eGFR) >20% from baseline defined WRF.
Results: Higher dose of losartan increased serum potassium. Episodes of HK>5 mmol/L and WRF occurred at least once in about 2/3 of the 
patients. WRF was associated with higher occurrence of HK, and vice versa. Baseline potassium, background mineralocorticoid receptor antagonists 
(MRAs), and to a marginal extent use of losartan 150 mg, were independently associated with incident HK, whereas a better baseline eGFR and 
white ethnicity were found protective. High dose losartan, MRA use and baseline eGFR were positively associated with incident WRF independently 
from age, female gender, lower ejection fraction, diabetes and ethnicity. High dose losartan improved outcome despite more frequent WRF and HK.
Conclusions: HK is very common in HF patients, with its incidence dose-dependently increased by losartan. Both HK and WRF can be predicted 
from baseline risk factors, and are therefore potentially preventable. Although associated to worse outcome, occurrence of any does not hinder the 
efficacy of high dose losartan and should not therefore deprive HF patients from this treatment.
